WallStreetZenWallStreetZen

NASDAQ: BBOT
Bridgebio Oncology Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Bridgebio Oncology Therapeutics earnings were -$134.0M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest BBOT earnings report on Dec 31, 2025 announced Q4 2025 earnings of -$38.8M, down 13.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, BBOT reported annual earnings of -$134.0M, with 80.5% growth.

BBOT earnings history

Current Revenue
$0.0
Current Earnings
-$134.0M
Current Profit Margin
0%

BBOT Return on Equity

Current Company
-85.9%
Current Industry
-31.4%
Current Market
28.9%
BBOT's Return on Equity (-85.9%)... subscribe to Premium to read more.
High Return on Equity Performance

BBOT Return on Assets

Current Company
-41.9%
Current Industry
-9.6%
BBOT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when BBOT announces earnings.

BBOT Return on Capital Employed

Current Company
-32.43%
Current Industry
-3.7%
BBOT's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BBOT vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
BBOT-$133.43M-$134.04MN/A-$4.30
RLMD-$57.39M-$57.39MN/A-$1.45
VOR-$687.45M-$695.98MN/A-$70.50
GYRE$12.84M$5.03M+79.37%$0.06
DSGN-$69.19M-$69.79MN/A-$1.22
View Top Biotech Stocks

Bridgebio Oncology Therapeutics Earnings Reports & History FAQ

What were Bridgebio Oncology Therapeutics's earnings last quarter?

On BBOT's earnings call on Invalid Date, Bridgebio Oncology Therapeutics (NASDAQ: BBOT) reported Q4 2025 earnings per share (EPS) of $2.19, up 100.26% year over year. Total BBOT earnings for the quarter were -$38.80 million. In the same quarter last year, Bridgebio Oncology Therapeutics's earnings per share (EPS) was -$833.69.

If you're new to stock investing, here's how to buy Bridgebio Oncology Therapeutics stock.

Is Bridgebio Oncology Therapeutics profitable or losing money?

As of the last Bridgebio Oncology Therapeutics earnings report, Bridgebio Oncology Therapeutics is currently losing money. Bridgebio Oncology Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$134.04 million, a 80.47% increase year over year.

What was BBOT's earnings growth in the past year?

As of Bridgebio Oncology Therapeutics's earnings date in Invalid Date, Bridgebio Oncology Therapeutics's earnings has grown year over year. BBOT earnings in the past year totalled -$134.04 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.